Network meta-analysis of oral Chinese patent medicine combined with SSRI for the treatment of depressive disorder in special population

ObjectiveInvestigating the therapeutic efficacy and safety of combined oral Chinese patent medicine with selective serotonin reuptake inhibitors (SSRIs) in special Homo sapiens populations with depressive disorders. MethodsChina National Knowledge Infrastructure(CNKI), Chinese Biomedical Literature Database(CBM), Chinese Academic Journal Database(CSPD), Chinese Science and Technology Journal Database(CCD), EMbase, Pubmed,Cochrane Library, and Web of Science were retrieved, and ClinicalTrials.gov was searched from the establishment of the database to October 2023. All included Rized controlled trials were assessed for quality using the Cochrane systematic evaluation manual.Network Meta-analysis was performed using the Stata 17.0 software. Results36 studies were included, and the total sample size included 3110 cases, including 1556 cases in the test group and 1554 cases in the control group. A total of Chinese patent medicines were included: Shugan Jieyu capsule, Xiaoyaosan , Wuling capsule, and Morinda officinalis oligose. The results of the network Meta-analysis showed that. Compared to antidepressant treatment with SSRI alone, Adolescent depressive disorder: In improving clinical efficiency, Wuling capsule combined with SSRI ranked the highest; In terms of improving the HAMD score, Xiaoyaosan ranked the highest; Geriatric depressive disorder: In improving clinical efficiency, Shugan Jieyu capsule combined with SSRI ranked the highest; In terms of improving the HAMD score, the Shugan Jieyu capsule combined with SSRI ranked the highest; Postpartum depression disorder: In improving clinical efficiency, the Shugan Jieyu capsule combined with SSRI ranked the highest; In terms of improving the HAMD score, the Shugan Jieyu capsule combined with SSRI ranked the highest; Perimenopausal depression disorder: In improving clinical efficiency, the Xiaoyaosan combined with SSRI ranked the highest; In terms of improving the HAMD score, the Wuling capsule combined with SSRI ranked the highest; ConclusionOn the basis of SSRI, the addition of Chinese patent medicine can improve the effectiveness and safety of clinical treatment. It is suggested that more high-quality RCT studies of Chinese patent medicine for depression disorders, especially in adolescent depression disorder, postpartum depression disorder, perimenopausal depression disorder, are conducted to provide stronger evidence. Trial registrationThis systematic review protocol has been registered on PROSPERO database(www.crd.york.ac.uk/prospero/) with number (CRD42022364242).